---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-057772"
form_type: "8-K"
ticker: "GERN"
cik: "0000886744"
company_name: "GERON CORP"
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T01:28:50.456008+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Geron reports Q3 2023 cash $381.9M, imetelstat FDA PDUFA June 16, 2024; new $100M ATM facility

## Summary
- Cash, cash equivalents and marketable securities $381.9M as of Sep 30, 2023; $28.3M from warrant exercises in Q3.
- FDA PDUFA action date June 16, 2024 for imetelstat NDA in lower-risk MDS; EMA review expected by end 2024.
- Entered into $100M at-market issuance sales agreement with B. Riley; replaces prior expiring facility; 3% commission.
- Michelle Robertson appointed EVP, CFO; total operating expenses in Q3 $47.8M vs $40.2M YoY; FY2023 expense guidance $200-210M.
- Company expects to fund operations through Q3 2025 with existing cash, projected imetelstat revenues and loan facility.

## SEC filing metadata
- accession: 0000950170-23-057772
- form_type: 8-K
- ticker: GERN
- cik: 0000886744
- company_name: GERON CORP
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886744/000095017023057772/0000950170-23-057772-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886744/000095017023057772/gern-20231101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-057772
- JSON: https://secwatch.observer/filing/0000950170-23-057772.json
- Plain text: https://secwatch.observer/filing/0000950170-23-057772.txt

## Key facts
- Earnings Releases
  GERON CORP reported three and nine months ended September 30, 2023 results: revenue $164,000 and $214,000, respectively.
  - Period: three and nine months ended September 30, 2023
  - Revenue: $164,000 and $214,000, respectively
  - Result: reported results
  source text: loan facility, will be sufficient to fund its projected operating requirements through the end of Q3 2025. Revenues for the three and nine months ended September 30, 2023, were $164,000 and $214,000, respectively, compared to $297,000 and $493,000 for the comparable 2022 periods. Revenues in both years primarily reflect estimated royalties from sales of
  evidence_url: https://www.sec.gov/Archives/edgar/data/886744/000095017023057772/0000950170-23-057772-index.htm
- Material Agreements
  GERON CORP entered into 2023 Sales Agreement with B. Riley Securities, Inc. valued at up to $100 million (effective 2023-11-01).
  - Action: entry
  - Agreement: atm program
  - Counterparty: B. Riley Securities, Inc.
  - Value: up to $100 million
  - Effective: 2023-11-01
  source text: On November 1, 2023, Geron Corporation (the “Company”) entered into an At Market Issuance Sales Agreement (the “2023 Sales Agreement”) with B. Riley Securities, Inc. (“B. Riley Securities”), pursuant to which the Company may issue and sell shares of its common stock having an aggregate offering price of up to $100 million from time to time through B. Riley Securities as its sales agent.
  evidence_url: https://www.sec.gov/Archives/edgar/data/886744/000095017023057772/0000950170-23-057772-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.